Taking GLP-1 medications like Ozempic is linked to a smaller risk of developing epilepsy than taking DPP-4 inhibitors. | Drug ...

Cassava Sciences shares fell after the company said the Food and Drug Administration had put a hold on its epilepsy drug trial. The stock fell 15% to $2.41 in after-hours trading Thursday. Through the ...

A new analysis suggests GLP 1 receptor agonists, the diabetes drugs that include semaglutide, dulaglutide and liraglutide, ...

A large US-based study has found that people with type 2 diabetes taking GLP-1 drugs such as Ozempic may be slightly less ...

Individuals with epilepsy and their caregivers want improved communication and a broader base of information from their ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) ...

Glucagon-like peptide-1 receptor agonist therapy is associated with a reduced risk for epilepsy in adults with type 2 diabetes mellitus.

During this symposium, leading international epileptologists discussed the key challenges and opportunities that currently ...

Cassava Sciences (SAVA) stock slips as the company delays an epilepsy trial for its lead asset simufilam after FDA concerns.

Cassava Sciences confirms an FDA clinical hold on its simufilam epilepsy trial, delaying plans and requiring more data despite strong cash reserves.

Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...